Table 2.
CAN Outcomes in 1,211 subjects with EDIC year 13/14 autonomic measurements
| DCCT | DCCT | EDIC | ||
|---|---|---|---|---|
| Test | Group | Baseline | Closeout | Year 13/14 |
| CAN prevalence, No. (%)d | INT | 24 (3.9) | 43 (7.1) | 179 (28.9)b |
| CONV | 31 (5.3) | 57 (9.9) | 208 (35.2) | |
| R-R Variation < 15, No. (%) | INT | 20 (3.3) | 39 (6.6) | 147 (23.8)b |
| CONV | 25 (4.3) | 53 (9.5) | 178 (30.2) | |
| Valsalva Ratio ≤ 1.5, No. (%) | INT | 31 (5.2) | 42 (7.4) | 145 (26.0) |
| CONV | 30 (5.2) | 51 (9.3) | 146 (30.4) | |
| R-R Variation, mean ±SD | INT | 48.5 ± 22.6 | 41.4 ± 20.5 | 29.6 ± 18.9a |
| CONV | 47.4 ± 21.2 | 39.3 ± 20.1 | 26.1 ± 17.5 | |
| Adjusted R-R Variation, mean ±SD c | INT | 48.8 ± 21.3 | 41.8 ± 19.5b | 29.9 ± 17.4a |
| CONV | 47.0 ± 21.4 | 38.9 ± 19.4 | 25.6 ± 17.5 | |
| Valsalva Ratio, mean ±SD | INT | 2.1 ± 0.4 | 2.0 ± 0.4 | 1.8 ± 0.4 |
| CONV | 2.0 ± 0.4 | 2.0 ± 0.4 | 1.8 ± 0.4 | |
| Adjusted Valsalva Ratio, mean ±SD c | INT | 2.1 ± 0.5 | 2.0 ± 0.5 | 1.8 ± 0.2b |
| CONV | 2.0 ± 0.5 | 2.0 ± 0.5 | 1.7 ± 0.4 | |
| Postural hypotension, No. (%) | INT | 2 (0.3) | 3 (0.5) | 11 (1.8) |
| CONV | 3 (0.5) | 4 (0.7) | 9 (1.6) |
CAN Cardiac autonomic neuropathy, EDIC Epidemiology of Diabetes Interventions and Complications, DCCT Diabetes Control and Complications Trial, INT intensive, CONV conventional.
a
P < 0.01 and
b
P<0.05 for treatment group differences by the Wilcoxon rank-sum test or chi-square test comparing INT and CONV treatment groups.
c
Means adjusted for DCCT baseline age, sex, cohort assignment and duration in the DCCT study.
d
CAN prevalence is defined as any one of the following conditions: R-R variation < 15; R-R variation < 20 in combination with Valsalva ratio ≤ 1.5; or Postural hypotension.